Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study
Open Access
- 20 February 2017
- journal article
- research article
- Published by Springer Nature in Journal of Intensive Care
- Vol. 5 (1) , 19
Abstract
Direct hemoperfusion therapy with polymyxin B immobilized fiber cartridges (PMX-DHP) is widely used for septic shock in Japan and parts of Europe. Although this treatment is usually administered for 2 h, the optimal duration has not been established. This retrospective study compared the effects of prolonged and conventional PMX-DHP durations (2 and 12 h, respectively) for septic shock. Between October 2013 and March 2015, 18 patients underwent conventional PMX-DHP, and between April 2015 and May 2016, 18 patients underwent prolonged PMX-DHP. The primary outcome was the vasopressor dependency index during the 12 h after starting the first PMX-DHP session. The vasopressor dependency index was calculated as (inotropic score)/(mean blood pressure). The patients’ characteristics were almost similar in the conventional and prolonged PMX-DHP groups. The major site of infection was the abdomen in both groups (61 and 72%, respectively). The conventional PMX-DHP group had mean blood pressure values of 68.4 ± 8.9 mmHg and 78.2 ± 16.9 mmHg at 0 and 12 h after starting PMX-DHP (P = 0.13). The prolonged PMX-DHP group had mean blood pressure values of 70.3 ± 15.7 mmHg and 87.7 ± 16.9 mmHg at 0 and 12 h after starting PMX-DHP (P = 0.004). The conventional PMX-DHP group had vasopressor dependency index values of 0.52 ± 0.29 and 0.39 ± 0.25 at 0 and 12 h after starting PMX-DHP (P = 0.29). The prolonged PMX-DHP group had vasopressor dependency index values of 0.50 ± 0.26 and 0.28 ± 0.18 at 0 and 12 h after starting PMX-DHP (P = 0.01). Hospital mortality was similar in both groups (8/18 [44%] and 8/18 [44%]). These findings suggest that prolonged PMX-DHP provides more sustained circulatory stabilization compared to conventional PMX-DHP. However, our study failed to detect any improvement in mortality. Well-designed prospective trials are needed to examine the clinical outcomes of prolonged PMX-DHP and to identify the optimal duration of PMX-DHP.Keywords
This publication has 12 references indexed in Scilit:
- Developing a New Definition and Assessing New Clinical Criteria for Septic ShockJAMA, 2016
- Clinical Effects of a Longer Duration of Polymyxin B‐Immobilized Fiber Column Direct Hemoperfusion Therapy for Severe Sepsis and Septic ShockTherapeutic Apheresis and Dialysis, 2015
- Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trialIntensive Care Medicine, 2015
- The Japanese guidelines for the management of sepsisJournal of Intensive Care, 2014
- Polymyxin B-immobilized fiber column hemoperfusion removes endotoxin throughout a 24-hour treatment periodJournal of Critical Care, 2014
- Efficacy of endotoxin adsorption therapy (polymyxin B hemoperfusion) for methicillin-resistant Staphylococcus aureus toxic shock syndrome: a case report about five patients.2013
- A LONGER DURATION OF POLYMYXIN B-IMMOBILIZED FIBER COLUMN HEMOPERFUSION IMPROVES PULMONARY OXYGENATION IN PATIENTS WITH SEPTIC SHOCKShock, 2009
- Early Use of Polymyxin B Hemoperfusion in Abdominal Septic ShockJAMA, 2009
- A PILOT-CONTROLLED STUDY OF A POLYMYXIN B-IMMOBILIZED HEMOPERFUSION CARTRIDGE IN PATIENTS WITH SEVERE SEPSIS SECONDARY TO INTRA-ABDOMINAL INFECTIONShock, 2005
- Extracorporeal Endotoxin Removal by Polymyxin B Immobilized Fiber Cartridge: Designing and Antiendotoxin Efficacy in the Clinical ApplicationTherapeutic Apheresis, 1998